Abstract:Drug-induced liver injury (DILI) encompasses a spectrum of clinical disease ranging from mild biochemical abnormalities to acute liver failure. The majority of adverse liver reactions are idiosyncratic, occurring in most instances 5-90 days after the causative medication was last taken. The diagnosis of DILI is clinical, based on history, probability of the suspect medication as a cause of liver injury and exclusion of other hepatic disease. DILI can be hepatocellular (predominant rise in alanine transaminase), cholestatic (predominant rise in alkaline phosphatase) or mixed liver injury. An elevated bilirubin level more than twice the upper limit of normal in patients with hepatocellular liver injury implies severe DILI, with a mortality of approximately 10% and with an incidence rate of 0.7-1.3 per 100,000. Although acute liver failure is rare, 13-17% of all acute liver failure cases are attributed to idiosyncratic drug reactions. Response to drug withdrawal may be delayed up to 1 year with cholestatic liver injury with occasional subsequent progressive cholestasis known as the vanishing bile duct syndrome. Overall, chronic disease may occur in up to 6% even if the offending drug is withdrawn. Antibiotics and NSAIDs are the most common cause of DILI. Statins rarely cause significant liver injury whereas antiretroviral therapy is associated with hepatotoxicity in 10% of treated patients. Multiple mechanisms of DILI have been implicated, including TNF-alpha-activated apoptosis, inhibition of mitochondrial function and neoantigen formation. Risk factors for DILI include age, sex and genetic polymorphisms of drug-metabolising enzymes such as cytochrome P450. In patients with human immunodeficiency virus, the presence of chronic viral hepatitis increases the risk of antiretroviral therapy hepatotoxicity. Over the next decade, the combination of accurate case ascertainment of DILI via clinical networks and the application of genomics and proteomics will hopefully lead to accurate prediction of risk of DILI, so that pharmacotherapy can be optimised with avoidance of adverse hepatic events.

S4241 Attack of the Maca: Drug-Induced Liver Injury Secondary to Lepidium meyenii

S4443 A Case of Drug-Induced Liver Injury Caused by Mushroom Gummy Ingestion

S4397 Drug-Induced Liver Injury Secondary to Recent Ozempic use

Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective

S4339 Herb Hazard: Ashwagandha Induced Liver Injury

S4684 Rare Case of Drug-Induced Liver Injury Secondary to Benadryl Use

Lepidium meyenii Walp (red maca) Supplementation Prevents Acrylamide-Induced Oxidative Stress and Liver Toxicity in Rats: Phytochemical Composition by UHPLC–ESI–MS/MS

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Hepatic Macrophages in Drug-Induced Liver Injury

Severe Drug-Induced Liver Injury From Over-the-Counter Medication

S4244 Acute Hepatocellular Injury Induced by Pre-Workout Supplements

A unusual presentation of liver failure caused by Ibuprofen-sustained release capsules: A case report

S4537 Turmeric's Bitter Twist: Drug-Induced Liver Injury from Turmeric Supplements

Clinical Characteristics of Patients with Drug-induced Liver Injury.

S4431 A Severe Case of Drug-Induced Liver Injury After Ingestion of Amoxicillin-Clavulanic Acid

Idiosyncratic drug-induced liver injury: an overview

Incidence and risk factors of drug-induced liver injury

LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults

LIVER INJURY INDUCED BY HERBAL AND DIETARY SUPPLEMENTS: A POOLED ANALYSIS OF CASE REPORTS

Guidance for the Clinical Evaluation of Traditional Chinese Medicine-Induced Liver Injuryissued by China Food and Drug Administration

Metamizole as a Rare Cause of Drug-Induced Liver Injury